Expect a variety of topics to be covered this week.
Here's what to look forward to this week:
Successfully managing osteoporosis in postmenopausal women revolves around risk factors and risk-assessment tools for identifying women who are candidates for pharmacologic therapy, according to an updated position statement from the North American Menopause Society (NAMS).
Despite advantages to its use, the procedure remains underutilized. Two experts outline an approach for getting started.
A Swedish cohort study in the journal Environment International has found that women of fertile age who were exposed to high levels of perfluorinated substances (PFAS) in drinking water were significantly more likely to subsequently have a diagnosis of polycystic ovarian syndrome (PCOS) and possibly uterine leiomyoma (or uterine fibroids [UFs]), but not endometriosis.
FDA grants 510(k) clearance to chemiluminescence-based immunoassay
Published: January 10th 2025 | Updated: January 10th 2025The automated chemiluminescence-based immunoassay has received clearance for free testosterone, providing enhanced diagnostic options to a multitude of conditions.
Read More